143 related articles for article (PubMed ID: 32923387)
1. Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors.
Chowdhury S; Mainwaring P; Zhang L; Mundle S; Pollozi E; Gray A; Wildgust M
Front Oncol; 2020; 10():1349. PubMed ID: 32923387
[No Abstract] [Full Text] [Related]
2. Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan.
Shiota M; De Moor R; Koroki Y; Yu DY; Wu DB
Curr Med Res Opin; 2022 Aug; 38(8):1351-1359. PubMed ID: 35770513
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
4. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
Adunlin G; Cyrus JW; Dranitsaris G
Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
[TBL] [Abstract][Full Text] [Related]
5. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cremolini C; Antoniotti C; Pietrantonio F; Berenato R; Tampellini M; Baratelli C; Salvatore L; Marmorino F; Borelli B; Nichetti F; Bironzo P; Sonetto C; Bartolomeo MD; Braud F; Loupakis F; Falcone A; Di Maio M
Cancer Res Treat; 2017 Jul; 49(3):834-845. PubMed ID: 27857020
[TBL] [Abstract][Full Text] [Related]
6. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
7. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
8. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Palumbo A; Gay F; Cavallo F; Di Raimondo F; Larocca A; Hardan I; Nagler A; Petrucci MT; Hajek R; Pezzatti S; Delforge M; Patriarca F; Donato F; Cerrato C; Nozzoli C; Yu Z; Boccadifuoco L; Caravita T; Benevolo G; Guglielmelli T; Vincelli D; Jacques C; Dimopoulos MA; Ciccone G; Musto P; Corradini P; Cavo M; Boccadoro M
J Clin Oncol; 2015 Oct; 33(30):3459-66. PubMed ID: 26282661
[TBL] [Abstract][Full Text] [Related]
9. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
Petrelli F; Barni S
Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
[TBL] [Abstract][Full Text] [Related]
10. The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan.
Mori A; Hashimoto K; Koroki Y; Wu DB; Masumori N
Curr Med Res Opin; 2019 Oct; 35(10):1745-1750. PubMed ID: 31084438
[No Abstract] [Full Text] [Related]
11. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
13. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
Colloca G; Venturino A
Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
15. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
[TBL] [Abstract][Full Text] [Related]
16. Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials.
Emura T; Sofeu CL; Rondeau V
Stat Methods Med Res; 2021 Dec; 30(12):2634-2650. PubMed ID: 34632882
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
18. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.
Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Ikeda M
Endocr Relat Cancer; 2017 Sep; 24(9):475-483. PubMed ID: 28684542
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
